DRUG DISCOVERY FEATURED ARTICLES & APPLICATIONS

• 

  How To Prepare A Facility For The Biopharmaceutical Revolution

  Drug discovery is an inherently inefficient process. It takes thousands of failed compounds before one can get approved as safe and efficacious, and this effort does not come at a low cost. Because of this, the industry is constantly looking for ways to bring safe, compliant, and profitable drugs to market faster and cheaper. Patheon facility in Brisbane, Australia, exemplifies the facility needed to survive the future of pharma. But how did they do it?

• Pharmaceutical Customers In An Outsourcing Provider Merger -- Part 3 Of Interview With CEO of Newly Formed DPx Holdings B.V.

  This final article in our series featuring Jim Mullen, CEO of newly formed DPx Holdings B. V., discusses how to keep the focus on customers during M&A activity, and the broader transformation of sponsor–provider relationships in the pharmaceutical outsourcing industry.

• Quality, Capacity And Job Security In A CMO Industry Merger -- Part 2 Of Our Interview With CEO Of Newly Formed DPx Holdings B.V.

  This spring Jim Mullen became CEO of DPx Holdings B.V., formed in a $2.65 billion transaction combining JLL Partners’ assets Patheon and Banner Life Sciences, with Royal DSM’s Pharmaceuticals business. In an interview with Outsourced Pharma, Mullen discusses three key components in a merger: quality, capacity and job security.

  With a merger nearing completion and the integration plans underway, Mullen says you have to start with the fundamental ABCs of business. “There are three fundamental questions to get to day one: Do you have the right financial controls? Can you reliably continue to pay your suppliers? Can you receive cash and can you make payroll?

• Results of First Ever REMOTE Clinical Trial

  In the clinical research industry, we’re always evaluating things.  We evaluate drugs and biologics.  We evaluate medical devices.  We also evaluate research techniques.  Yes, we try trials.  We study studies.  That’s what Pfizer was doing when it launched its REMOTE pilot trial in early 2011 – evaluating the effectiveness of a study in which patients participated remotely, without ever having to visit a study site.  How would the results of the REMOTE study compare with those of a similar, completed, conventional study?  Would this innovative research approach be validated? By Laurie Meehan, Polaris Compliance Consultants, Inc.

• IMP Shipments: Too Big, Too Costly, Too Bad

  A client in the UK was initiating a new clinical trial, and shipping forty-two pallets of the IMP to Marken’s pharmaceutical service depot in the testing region created several challenges.

LATEST NEWS

• Lpath Reports Interim Data From Phase 2a Study For Anti-Cancer Drug, ASONEP

  Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, reported interim results in a Phase 2a single-arm, open-label trial where ASONEP™ is being investigated as a treatment for metastatic renal cell carcinoma (RCC) in patients that have failed at least one therapy involving a VEGF inhibitor (e.g., Sutent®/ sunitinib maleate) and no more than one mTOR inhibitor (e.g., Afinitor®/everolimus), with a maximum of three failed treatments in all

• Incyte Announces Top-Line Results From RELIEF Trial Of Ruxolitinib In Patients With Polycythemia Vera
• Humacyte Receives Fast Track Designation For HumaGraft For Vascular Access In Hemodialysis Program
• Genocea Commences Phase 2 Dose Optimization Trial For GEN-003 HSV-2 Immunotherapy
• Exploring The Challenges In Drug Delivering System For Efficient Solutions

FEATURED PRODUCTS AND SERVICES

Purified G-Protein-coupled Receptors

Upstate Biotechnology is preparing the launch of its human G-Protein-Coupled Receptor (GPCR) product line

Micro Hi-Temp Submersible Logger

The Micro Hi-Temp Submersible Logger can record over 8,000 time-stamped temperature measurements in environments of –40°C to +125°C.

HP D300 Digital Dispenser

Fast and accurate determination of a candidate compound’s IC50 provides drug discovery biologists with valuable information for the development of new pharmaceuticals, yet traditional techniques are both time­ consuming and laborious, with no standardization across the industry.

HPLC Autosampler

The company offers a six-page, four-colorbrochure highlighting the features and benefits of its Endurance HPLC Autosampler, which allows for processing of virtually any well plate type (e.g. deep well, PCR well, 384-well) in addition to standard autosampler vials or micro vials.

Excipient Compatibility Testing

At Patheon, we'll put the experience of thousands of projects to work when helping you to achieve the ideal dose form for your new drug product.

ARCHIVED NEWSLETTER

• 07.07.14 -- Innovative Multimode Plate Reader Launched
• 06.06.14 -- Positive Data On Humanized Antibody In Two Models Of Osteoarthritis Announced
• 05.02.14 -- Integrated Phenotypic Screening And Target Deconvolution For Drug Discovery
• 04.04.14 -- Disposable Purification Solution To Lower Cost And Accelerate Drug Development
• 03.07.14 -- Investment In FISH Technologies For Leukemia And Lymphoma Testing